Total Payments
$302,018
2024 Payments
$58,487
Companies
26
Transactions
250
Medicare Patients
1,533
Medicare Billing
$245,472
Payment Breakdown by Category
Consulting$251,366 (83.2%)
Research$15,310 (5.1%)
Other$15,145 (5.0%)
Travel$14,988 (5.0%)
Food & Beverage$4,812 (1.6%)
Education$396.99 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $251,366 | 118 | 83.2% |
| Unspecified | $15,310 | 14 | 5.1% |
| Travel and Lodging | $14,988 | 33 | 5.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,145 | 5 | 4.4% |
| Food and Beverage | $4,812 | 76 | 1.6% |
| Honoraria | $2,000 | 1 | 0.7% |
| Education | $396.99 | 3 | 0.1% |
Payments by Type
General
$286,708
236 transactions
Research
$15,310
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $58,930 | 37 | $0 (2024) |
| Celgene Corporation | $43,367 | 31 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $36,138 | 14 | $0 (2020) |
| Janssen Global Services, LLC | $27,377 | 25 | $0 (2023) |
| PFIZER INC. | $20,935 | 17 | $0 (2024) |
| Incyte Corporation | $14,201 | 3 | $0 (2022) |
| Janssen Research & Development, LLC | $14,141 | 14 | $0 (2024) |
| F. Hoffmann-La Roche AG | $10,804 | 9 | $0 (2024) |
| Janssen Biotech, Inc. | $10,195 | 19 | $0 (2024) |
| ABBVIE INC. | $9,171 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $58,487 | 42 | GlaxoSmithKline, LLC. ($21,606) |
| 2023 | $33,235 | 34 | GlaxoSmithKline, LLC. ($7,435) |
| 2022 | $43,695 | 27 | Incyte Corporation ($14,201) |
| 2021 | $26,082 | 20 | Janssen Global Services, LLC ($10,165) |
| 2020 | $42,385 | 20 | Celgene Corporation ($14,500) |
| 2019 | $40,070 | 39 | Takeda Pharmaceuticals U.S.A., Inc. ($18,023) |
| 2018 | $33,410 | 37 | Takeda Pharmaceuticals U.S.A., Inc. ($15,805) |
| 2017 | $24,655 | 31 | Celgene Corporation ($12,588) |
All Payment Transactions
250 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $684.52 | Research |
| Study: Ph I of FcRH5 CD3 in multiple myeloma | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $365.92 | Research |
| Study: Ph I of FcRH5 CD3 in multiple myeloma | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,540.00 | General |
| 12/04/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $1,140.00 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | Kite Pharma, Inc. | Tecartus (Drug) | Consulting Fee | Cash or cash equivalent | $365.00 | General |
| Category: CELLT | ||||||
| 11/29/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $325.00 | General |
| 11/06/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $480.00 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $4,800.00 | General |
| 10/23/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $337.50 | General |
| 10/08/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $4,800.00 | General |
| 10/03/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $4,830.00 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $75.00 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $30.00 | General |
| Category: ONCOLOGY | ||||||
| 10/01/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $380.00 | General |
| 09/28/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $39.03 | General |
| Category: Oncology | ||||||
| 09/27/2024 | Janssen Biotech, Inc. | TALVEY (Biological), TECVAYLI, CARVYKTI | Food and Beverage | In-kind items and services | $64.24 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $36.80 | General |
| Category: Oncology | ||||||
| 09/05/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $990.00 | General |
| Category: ONCOLOGY | ||||||
| 09/05/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $75.00 | General |
| Category: ONCOLOGY | ||||||
| 09/05/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $30.00 | General |
| Category: ONCOLOGY | ||||||
| 08/06/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| 08/02/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug) | Consulting Fee | Cash or cash equivalent | $1,860.00 | General |
| Category: Oncology | ||||||
| 06/21/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $7,150.96 | General |
| 06/18/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 06/06/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $685.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma | Amgen Inc. | $7,556 | 1 |
| Scientific Advisory Board | Ichnos Sciences Inc. | $5,773 | 2 |
| Ph I of FcRH5 CD3 in multiple myeloma | F. Hoffmann-La Roche AG | $1,050 | 2 |
| A PHASE II, OPEN LABEL, RANDOMIZED, TWO-ARM STUDY TO INVESTIGATE THE E | GlaxoSmithKline, LLC. | $930.77 | 9 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 381 | 750 | $154,944 | $59,823 |
| 2022 | 7 | 388 | 861 | $143,155 | $72,820 |
| 2021 | 6 | 384 | 663 | $123,016 | $64,331 |
| 2020 | 8 | 380 | 577 | $112,255 | $48,497 |
Total Patients
1,533
Total Services
2,851
Medicare Billing
$245,472
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 231 | 481 | $78,625 | $33,877 | 43.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 21 | 92 | $27,508 | $9,089 | 33.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 38 | 45 | $12,028 | $4,988 | 41.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 31 | 31 | $13,357 | $4,514 | 33.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 55 | $11,440 | $3,612 | 31.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 14 | 14 | $8,204 | $2,015 | 24.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 13 | 13 | $2,015 | $873.60 | 43.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 16 | 19 | $1,767 | $854.05 | 48.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 240 | 586 | $83,110 | $45,127 | 54.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 33 | 139 | $25,854 | $11,807 | 45.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 38 | 59 | $13,250 | $6,808 | 51.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 36 | 36 | $12,780 | $5,257 | 41.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 15 | 15 | $4,875 | $2,365 | 48.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 14 | 14 | $2,170 | $838.48 | 38.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 12 | 12 | $1,116 | $617.11 | 55.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 119 | 197 | $43,590 | $23,386 | 53.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 177 | 287 | $40,695 | $23,249 | 57.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 25 | 114 | $20,979 | $9,948 | 47.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 40 | 40 | $14,200 | $6,323 | 44.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 12 | 14 | $1,847 | $752.44 | 40.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 11 | 11 | $1,705 | $673.09 | 39.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 105 | 166 | $36,760 | $14,867 | 40.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 38 | 142 | $25,467 | $12,813 | 50.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 113 | 139 | $20,195 | $8,888 | 44.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 29 | 29 | $10,295 | $4,094 | 39.8% |
About Dr. Adam Cohen, MD
Dr. Adam Cohen, MD is a Medical Oncology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1245201029.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Adam Cohen, MD has received a total of $302,018 in payments from pharmaceutical and medical device companies, with $58,487 received in 2024. These payments were reported across 250 transactions from 26 companies. The most common payment nature is "Consulting Fee" ($251,366).
As a Medicare-enrolled provider, Cohen has provided services to 1,533 Medicare beneficiaries, totaling 2,851 services with total Medicare billing of $245,472. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology
- Location Philadelphia, PA
- Active Since 01/30/2006
- Last Updated 06/05/2013
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1245201029
Products in Payments
- NINLARO (Drug) $33,828
- ELREXFIO (Drug) $15,220
- CARVYKTI (Drug) $12,717
- DARZALEX (Biological) $9,380
- CAR-T (Drug) $5,987
- BLENREP (Biological) $5,650
- EMPLICITI (Biological) $5,094
- ZEPOSIA (Drug) $3,300
- DARZALEX (Drug) $2,495
- SGNCD352A (Biological) $2,090
- ADCETRIS (Biological) $1,939
- TECVAYLI (Biological) $1,575
- VENCLEXTA (Drug) $893.66
- IMBRUVICA (Drug) $505.00
- Tecartus (Drug) $365.00
- Revlimid (Drug) $272.89
- NO PRODUCT DISCUSSED (Drug) $86.00
- MYRBETRIQ (Drug) $83.26
- TALVEY (Biological) $64.24
- XPOVIO (Drug) $53.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Philadelphia
Daniel Haller, Md, MD
Medical Oncology — Payments: $744,976
Medical Oncology $744,976
Dr. Jean-Pierre Issa, M.d, M.D
Medical Oncology — Payments: $223,097
Medical Oncology $223,097
Alexander Perl, Md, MD
Medical Oncology — Payments: $218,549
Medical Oncology $218,549
Carl June, Md, MD
Medical Oncology — Payments: $140,824
Medical Oncology $140,824
Anthony Olszanski, M.d, M.D
Medical Oncology — Payments: $131,641
Medical Oncology $131,641
Charalambos Andreadis, Md, MD
Medical Oncology — Payments: $126,184
Medical Oncology $126,184